Verastem, Inc. filings document a Nasdaq-listed biopharmaceutical company with common stock trading under VSTM and a business focused on RAS/MAPK pathway-driven cancers. Its 8-K reports furnish corporate presentations, financial-result releases, strategic updates, clinical data disclosures, and Regulation FD materials for AVMAPKI FAKZYNJA CO-PACK, RAMP clinical programs, and VS-7375.
The company’s SEC records also cover capital-structure activity, including common stock and pre-funded warrant offerings, and proxy disclosures for board matters, executive compensation, equity awards, and shareholder voting. These filings frame Verastem’s commercialization, pipeline development, governance, financing, and public-company reporting obligations.
Verastem, Inc. reports a Form 144 notice for a proposed sale of 8,333 common shares previously received as a restricted stock grant on 06/18/2024. The sale is to be executed through Jefferies LLC on or about 10/09/2025 with an aggregate market value of $74,497.02. The filing shows 62,000,000 shares outstanding and indicates no sales by the same person in the prior three months. The notice includes the standard representation that the seller does not possess undisclosed material information and references Rule 10b5-1 trading-plan language.
Insider sale to cover tax withholding: Verastem, Inc. CFO Daniel Calkins reported two small sales of common stock tied to restricted stock unit vesting. On 09/22/2025 he sold 57 shares at $9.08 and on 09/24/2025 he sold 25 shares at $9.23, reducing his beneficial ownership from 109,920 to 109,838 shares. The Form 4 states these sales were made to satisfy statutory withholding obligations associated with RSU vesting, not an open-market disposition for other purposes.
Brian M. Stuglik, a director of Verastem, Inc. (VSTM), reported a sale of 587 shares of common stock on 09/16/2025 at $9.99 per share. The filing states the shares were sold to satisfy statutory withholding obligations arising from the vesting of restricted stock units. After the transaction, the reporting person beneficially owns 101,739 shares in a direct capacity. The Form 4 indicates it was filed by one reporting person and includes an explanatory note that the disposition was for tax withholding tied to RSU vesting.
Verastem, Inc. (VSTM) director Robert E. Gagnon reported a sale of 281 shares of common stock on 09/16/2025 at a price of $9.99 per share, reducing his direct holdings to 41,961 shares. The filing states the shares were sold solely to satisfy statutory withholding for vested restricted stock units. The Form 4 was signed by an attorney-in-fact on 09/18/2025. No options, warrants, or other derivative transactions are reported in this filing.
Insider sale to satisfy tax withholding — The Form 4 shows reporting person Paterson Dan, identified as Verastem, Inc. (VSTM) Director and President and CEO, reported a transaction dated 09/16/2025. The filing discloses a sale of 390 shares of common stock at $9.99 per share, executed to satisfy statutory withholding related to the vesting of restricted stock units. After the sale, the reporting person beneficially owned 442,117 shares directly. The form was signed by an attorney‑in‑fact on 09/18/2025. The filing contains no other transactions, derivatives, or additional explanatory items.
Verastem, Inc. submitted an 8-K reporting a material event: the company furnished a Corporate Presentation dated September 8, 2025. The filing identifies the company common stock symbol VSTM listed on The Nasdaq Capital Market and is signed by Chief Executive Officer Daniel W. Paterson. The cover references communications categories under Securities Act and Exchange Act rules including written communications under Rule 425 and pre‑commencement/soliciting communications under Rules 14a-12, 14d-2(b), and 13e-4(c). No financial tables, earnings figures, transactions, or additional narrative details appear in the provided text.
Form 144 filed for Verastem, Inc. (VSTM) reporting a proposed sale of 31,790 common shares through Raymond James & Associates on 09/17/2025 on NASDAQ with an aggregate market value of $310,429.00. The filing lists total shares outstanding of 63,043,373. The securities were acquired as compensation (RSUs) in multiple grants between 03/11/2013 and 12/31/2021, with individual grant sizes shown (for example, 9,532 shares on 12/31/2020 and 9,216 on 08/11/2021). The filer reports no securities sold in the past three months and affirms no undisclosed material adverse information.
OrbiMed Advisors LLC reports holding 1,333,333 warrants to purchase Verastem, Inc. common stock, representing 2.4% of the class. The filing shows OrbiMed has shared voting and dispositive power over these warrants but no sole voting or dispositive power. The reporting person states the warrants are held on behalf of other persons and that investment and voting power are exercised through a management committee of three named members who each disclaim beneficial ownership. The filing certifies the position is not held to change or influence control of Verastem.
RTW Investments, LP and Roderick Wong report beneficial ownership of 5,626,803 shares of Verastem, Inc. common stock, representing 9.99% of the outstanding shares on a fully exercised basis. The percentage calculations assume exercise of warrants to purchase 1,375,187 shares and use a base of 54,949,170 shares outstanding as reported by the company on May 12, 2025.
The filing shows shared voting and dispositive power over the reported shares (no sole voting or dispositive power). The RTW Funds, including RTW Master Fund, Ltd., have rights to dividends or sale proceeds for certain shares. Item 10 certifies the holdings were acquired in the ordinary course and not to change or influence control, other than activities related to a nomination under 240.14a-11.
Verastem Inc. is reported to have a substantial passive investor position held by Balyasny-related entities and Dmitry Balyasny totaling 5,777,396 shares, equal to 9.99% of the company's 54,949,170 outstanding shares (basis: the issuer's outstanding share count as of May 12, 2025). The reported position includes 1,571,428 shares issuable upon exercise of warrants, but those warrants cannot be exercised to the extent doing so would cause beneficial ownership to exceed the 9.99% blocker. The shares are held through Atlas Diversified Master Fund, Ltd. as the direct holder while Balyasny entities serve as manager/owners of the reporting group. The filing certifies the holdings are held in the ordinary course of business and not for the purpose of changing or influencing control.